216 related articles for article (PubMed ID: 32189402)
1. Efficacy and safety of bexarotene combined with photo(chemo)therapy for cutaneous T-cell lymphoma.
Morita A; Tateishi C; Muramatsu S; Kubo R; Yonezawa E; Kato H; Nishida E; Tsuruta D
J Dermatol; 2020 May; 47(5):443-451. PubMed ID: 32189402
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Efficacy and Safety of Bexarotene and Photo(Chemo)Therapy Combination Therapy and Bexarotene Monotherapy for Cutaneous T-Cell Lymphoma.
Morita A; Tateishi C; Ikumi K; Hayashi D; Nakada A; Nishihara H; Torii K; Nishida E; Tsuruta D
Dermatol Ther (Heidelb); 2022 Mar; 12(3):615-629. PubMed ID: 35084694
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of bexarotene for Japanese patients with cutaneous T-cell lymphoma: The results of a phase 2 study (B-1201).
Hamada T; Tokura Y; Sugaya M; Ohtsuka M; Tsuboi R; Nagatani T; Kiyohara E; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Saida T; Iwatsuki K
J Dermatol; 2019 Jul; 46(7):557-563. PubMed ID: 31090237
[TBL] [Abstract][Full Text] [Related]
5. Case series of cutaneous T-cell lymphomas treated with bexarotene-based therapy.
Fujimura T; Sato Y; Tanita K; Amagai R; Shimauchi T; Ogata D; Fukushima S; Miyashita A; Fujisawa Y; Kambayashi Y; Aiba S
J Dermatol; 2020 Jun; 47(6):636-640. PubMed ID: 32207181
[TBL] [Abstract][Full Text] [Related]
6. Bexarotene--an alternative therapy for progressive cutaneous T-cell lymphoma? First experiences.
Bohmeyer J; Stadler R; Kremer A; Nashan D; Muche M; Gellrich S; Luger T; Sterry W
J Dtsch Dermatol Ges; 2003 Oct; 1(10):785-9. PubMed ID: 16281814
[TBL] [Abstract][Full Text] [Related]
7. Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma.
Straus DJ; Duvic M; Horwitz SM; Hymes K; Goy A; Hernandez-Ilizaliturri FJ; Feldman T; Wegner B; Myskowski PL
Ann Oncol; 2014 Jan; 25(1):206-10. PubMed ID: 24285015
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
Illidge T; Chan C; Counsell N; Morris S; Scarisbrick J; Gilson D; Popova B; Patrick P; Smith P; Whittaker S; Cowan R
Br J Cancer; 2013 Nov; 109(10):2566-73. PubMed ID: 24136145
[TBL] [Abstract][Full Text] [Related]
9. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.
Stadler R; Otte HG; Luger T; Henz BM; Kühl P; Zwingers T; Sterry W
Blood; 1998 Nov; 92(10):3578-81. PubMed ID: 9808550
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
[TBL] [Abstract][Full Text] [Related]
12. Optimal combination with PUVA: rationale and clinical trial update.
Stadler R
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):29-32. PubMed ID: 17474357
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma.
Breneman D; Duvic M; Kuzel T; Yocum R; Truglia J; Stevens VJ
Arch Dermatol; 2002 Mar; 138(3):325-32. PubMed ID: 11902983
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance.
Hamada T; Morita A; Suga H; Boki H; Fujimura T; Hirai Y; Shimauchi T; Tateishi C; Kiyohara E; Muto I; Nakajima H; Abe R; Fujii K; Nishigori C; Nakano E; Yonekura K; Funakoshi T; Amano M; Miyagaki T; Makita N; Manaka K; Shimoyama Y; Sugaya M
J Dermatol; 2022 Feb; 49(2):253-262. PubMed ID: 34658060
[TBL] [Abstract][Full Text] [Related]
15. Optimizing bexarotene therapy for cutaneous T-cell lymphoma.
Talpur R; Ward S; Apisarnthanarax N; Breuer-Mcham J; Duvic M
J Am Acad Dermatol; 2002 Nov; 47(5):672-84. PubMed ID: 12399758
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.
Singh F; Lebwohl MG
J Am Acad Dermatol; 2004 Oct; 51(4):570-3. PubMed ID: 15389192
[TBL] [Abstract][Full Text] [Related]
19. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
20. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
